Vida International, a Taiwan drug making firm, was issued a warning over GMP violations last month. The FDA blamed the firm for not having a regular check of the quality features of one of its product before its release. The quality features involved identity, strength, purity, and other quality of the active ingredient.

The FDA further blamed Vida International for its failure to test the incoming raw materials that involved several other active ingredients along with the written specification before its use, complying with its identity. The warning demanded the firm to strengthen its written procedures to conduct the batch manufacturing and testing of the product before it finally releases the product for general use.